No Data
【Brokerage Focus】Guosen maintains an "Outperform" rating on CanSino (02162), stating that Siponimod is expected to have a first-mover advantage.
Jinwu Finance News | Guosen Securities Research pointed out that recently, Connoa (02162) received approval for the new indication of Supilumab for the treatment of seasonal allergic rhinitis, becoming the first IL4R monoclonal antibody globally approved for this treatment. This approval is based on a multicenter, randomized, double-blind, placebo-controlled phase 3 study, which showed that during the pollen season, compared to the standard treatment group (nasal steroid + antihistamines), after 2 weeks of treatment with Supilumab, patients experienced effective control of typical nasal allergy symptoms (runny nose, nasal congestion, nasal itching, sneezing), with significant differences between the groups.
Hong Kong stock movement | Kangnuo Ya (02162) rises over 4% as the seasonal allergic rhinitis IL-4Rα biological agent Sipuqibai monoclonal antibody is approved for market.
Conoya (02162) rose by more than 4%. As of the time of this report, it increased by 4.11%, reaching HKD 32.9, with a transaction volume of 8.4294 million HKD.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
New treatment plan for seasonal allergic rhinitis: The world's first seasonal allergic rhinitis IL-4Rα biologic, Kanyuda (Sopucimab), has been approved for market release.
Chengdu, February 7, 2025 /PR Newswire/ -- On February 7, 2025, Kangnuo announced that its self-developed new class 1 drug Kangyueda (Sipuqi Baidan Kangkai Injection) has been approved for marketing by the National Medical Products Administration for the treatment of seasonal allergic rhinitis (SAR). This is the third indication approved for Kangyueda, following approvals in September and December 2024 for the treatment of moderate to severe atopic dermatitis and chronic sinusitis with nasal polyps, making it the first IL-4Rα biologic approved globally for the treatment of seasonal allergic rhinitis, providing patients with a breakthrough therapeutic option. Focus on the unmet needs.
Keymed Biosciences Get China Nod for Supplementary NDA of Rhinitis Drug
